Toxoplasma gondii Seroprevalence and Trends in Women Presenting for Toxoplasma Screening in South-West Romania
by
, , and
Cristiana Luiza Radoi
1
,
Ovidiu Mircea Zlatian
2,3,*,
Maria Balasoiu
2,3,
Lucian Giubelan
4,5,
Andreea Cristina Stoian
4,
Livia Dragonu
4,5,
Alexandru Neacsu
1 and
Dominic Gabriel Iliescu
6,7 1
Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
2
Medical Laboratory, County Clinical Emergency Hospital of Craiova, 200349 Craiova, Romania
3
Microbiology Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
4
Infectious Diseases Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
5
“Victor Babes” Infectious Diseases and Pneumophtisiology Clinical Hospital, 200349 Craiova, Romania
6
Obstetric and Gynecology Department, County Clinical Emergency Hospital of Craiova, 200349 Craiova, Romania
7
Obstetric and Gynecology Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(8), 2057; https://doi.org/10.3390/microorganisms11082057
Submission received: 17 June 2023
/
Revised: 7 August 2023
/
Accepted: 9 August 2023
/
Published: 10 August 2023
(This article belongs to the Special Issue 10th Anniversary of Microorganisms: Past, Present and Future)
Abstract
:Toxoplasmosis, caused by the obligate intracellular protozoan parasite Toxoplasma gondii (T. gondii), is a globally prevalent zoonotic disease with potentially severe implications for immunocompromised individuals, pregnant women, and their fetuses/children. This study examined the prevalence of anti-T. gondii IgM and IgG antibodies in two groups of childbearing age women, including 653 participants in Group 1 (2013–2016) and 3221 participants in Group 2 (2019–2022). Our results revealed a decrease in the overall positivity rate of anti-T. gondii IgM antibodies from 2.32% to 1.06%, suggesting improved public health interventions over time. However, there were variations among different age groups and between rural and urban environments, with a significant decrease in urban areas across all age groups from Group 1 to Group 2. Regarding anti-T. gondii IgG antibodies, we did not observe a significant change in the seropositivity rate between the two groups. In the rural population with an age group over 35 years, we observed the highest positivity rate in Group 2. This study provided information on the risk factors and burden of toxoplasmosis in women of childbearing age with data that can be valuable to public health policies and the planning of healthcare measures for effective toxoplasmosis management.
1. Introduction
Toxoplasmosis is a parasitic infection caused by Toxoplasma gondii (T. gondii), an obligate intracellular protozoan parasite that infects a wide range of warm-blooded animal species, including cats, who can transmit the infection to humans [1,2]. This zoonotic disease has gained considerable attention due to its global prevalence and potential to cause severe complications in certain populations [3].
In immunocompetent individuals, T. gondii infection can be asymptomatic or exhibit mild flu-like symptoms [4]. In immunocompromised patients, for example, infected with HIV/AIDS or treated with immunosuppressive drugs, life-threatening conditions can occur, such as encephalitis and severe pneumonia [5,6,7].
Pregnant women are particularly at risk, as the fetus can be infected with T. gondii, leading to congenital toxoplasmosis, which can be manifested as a miscarriage, stillbirth, or severe neurological and ocular abnormalities in newborns [8,9]. The incidence of congenital toxoplasmosis is estimated to be 0.1 per 1000 live births [10]; the risk is higher if the mother has suggestive symptoms, such as lymphadenopathy [11]
The severity of fetal infection is inversely correlated with gestational age, with significant implications for fetal development if transmission occurs during the first trimester [8,9,12]. Beyond neurological disorders, toxoplasmosis can result in chorioretinitis (blurred vision and eye pain) [3,9]. Recent studies have reported a link between latent toxoplasmosis and behavioral or psychiatric alterations [13].
Several factors such as sanitation levels, temperature, humidity, host susceptibility as well as exposure to soil and domestic animals such as cats contribute toward the prevalence of toxoplasmosis [14,15]. Globally, seroprevalence in humans varies widely, from 10% to 90%, depending on geographical and cultural factors. [13,14,16,17,18,19,20,21,22,23,24,25].
For instance, highly endemic regions in certain parts of Africa have reported up to 90% seroprevalence, while some European populations have reported rates up to 60% [9]. A study of the seroprevalence of antibodies against TORCH agents (Toxoplasma gondii, Rubella virus, Cytomegalovirus, Herpes simplex virus, and other agents) shows that about 22.5% of the US population has evidence of previous exposure to T. gondii [26] indicating the need for continuous surveillance at both global and local levels for effective management strategies.
The economic burden of toxoplasmosis is substantial, with direct and indirect costs relating to diagnosis, treatment, and potential long-term sequelae [13]. These costs underscore the importance of increased awareness, accurate diagnostic methods, and effective prevention strategies to mitigate the impact of this parasitic infection [14].
Aim
Continuous surveillance at both global and local levels is essential for effective management. Accurate prevalence data of toxoplasmosis in the Romanian population is crucial to effectively prioritize public health policy, allocate funding for interventions and plan healthcare measures with the aim of reducing the burden of toxoplasmosis on maternal and neonatal health. To the best of our understanding, Romania lacks robust epidemiological studies supported by rigorous statistical controls. The collection of epidemiological data has predominantly been conducted retrospectively, meaning they are deprived of requisite calculations for statistical significance.
Our study sought to estimate T. gondii seroprevalence in fertile women from the South-West region of Romania using a rigorous academic approach. Furthermore, we aimed to investigate the relationship between demographic factors (such as area of residence and age) and T. gondii seroprevalence in two time periods (2013–2016, 2019–2022).
2. Materials and Methods
Study design. The study was retrospective, observational, and cross-sectional and was carried out on two groups of childbearing-age women who presented consecutively at the County Clinical Emergency Hospital of Craiova, Romania, in two time periods: between 2013 and 2016 (Group 1) and 2019 and 2022 (Group 2). Group 1 comprised 653 participants, while Group 2 had 3221 participants.
Participants. The study participants were Romanian women of childbearing age with residence in counties within the South-West region of Romania (Dolj, Gorj, Olt, Mehedinti, Valcea). The women were addressed to the hospital for the routine screening of antibodies against TORCH agents.
Data collection. For each participant, we recorded the age, area of residence, and the results of laboratory testing for anti-T. gondii IgM and IgG antibodies.
Laboratory testing for anti-T. gondii IgM and IgG antibodies. T. gondii serology was assessed during the first-trimester standard evaluation. Negative IgG cases were reassessed during the second trimester (24–25 gestational weeks) and third trimester (30–33 gestational weeks). The titers of IgM and IgG antibodies were determined by two different methods. For Group 1 (2013–2016), we used an immune electro-chemical luminescence assay with the analyzer Cobas E601 (Roche Diagnostics, Basel, BS, Switzerland), and for Group 2, we used an immune chemiluminescence assay with the analyzer Architect i1000 (Abbott, Abbott Park, IL, USA). We used commercial reagents provided by the manufacturers of these analyzers (Roche and Abbott). The analyzers’ proprietary software (version 0601) classified the tests as positive or negative according to cut-off values.
Therapeutic protocol. Pregnant women or women that planned pregnancy with confirmed T. gondii infection were referred to the Department of Infectious Diseases, where oral spiramycin at 1 g and 3 times daily were recommended to prevent transmission to the fetus. The regimen was started as soon as possible after serological diagnosis and continued throughout pregnancy. In pregnant women, amniocentesis was performed at 20 to 24 gestational weeks to investigate fetal infection. Ultrasound monitoring for the presence of fetal infection markers was indicated.
Statistical analysis. Data were exported from the hospital software HIPOCRATE (version H3 Concept) in the statistical software STATA 17 (Statacorp Ltd., College Station, TX, USA). Numerical data were expressed as the mean (standard deviation), and count data were expressed as the count (percentage). We used the Chi-squared test to assess the differences between Group 1 and Group 2, using a statistical significance level of p < 0.05. The age differences between Group 1 and Group 2 were tested using Student’s t-test as age was normally distributed in both groups.
We used the software Adobe Illustrator version 27.7 (Adobe Inc, San Jose, CA, USA) to construct a map of toxoplasmosis prevalence in Dolj County, Romania, based on publicly available county maps, in which we only included towns with more than 20 subjects tested. The areas where we had prevalence data were colored according to the prevalence level.
Ethical issues. This study was approved by the Committee of Ethics and Academic and Scientific Deontology, Craiova, Romania (approval no. 84/16.09.2020). The study adheres to both ethical guidelines and the legal requirements of the country where it was conducted.
3. Results
3.1. Anti-Toxoplasma gondii IgM Antibodies
Demographic characteristics. Group 1 (2013–2016) consisted of 602 females, with fewer females from rural areas (34.21%). Group 2 (2019–2022) included 3014 females, with a higher proportion from rural areas (56.54%). The mean age remained consistent between the two groups (27.79 vs. 27.62, p = 0.537) (Table 1). Both groups had the highest number of tested women in the 26–30 years age group. Group 2 showed a slightly higher number of tested women in the >35 years age group (Table 2).
Seroprevalence results. The highest seroprevalence was noted in women below 20 years in Group 1 (3/57, 5.26%) and in those over 35 years in Group 2 (6/140, 1.76%). In Group 1, the 26–30 years age group presented with the lowest seroprevalence in rural areas (1.49%), while in Group 2, the lowest seroprevalence was in the 21–25 years age group in urban areas (0.44%) (Table 2 and Table 3).
We observed a significant decrease in the overall positive results for anti-T. gondii IgM antibodies from 2.32% in Group 1 to 1.06% in Group 2 (p = 0.012) (Table 2). In both Group 1 and Group 2, seroprevalence decreased from rural areas to urban areas (2.90% vs. 2.02% and 1.40% vs. 0.61%, respectively).
A significant decline in prevalence was observed in urban areas across all age groups from Group 1 to Group 2 (from 2.02% to 0.61%, p = 0.011), with a similar trend in rural areas (from 2.91% to 1.40%, p = 0.099), though this was not statistically significant (Table 2). In Group 1, the prevalence was higher in urban areas for women under 30 years, while in Group 2, rural areas showed a higher prevalence.
A descending trend in positive results was observed in women under 20 years between the two groups, both in rural (2.70% vs. 1.80%) and urban areas (10.00% vs. 0.97%, p = 0.017) (Table 2 and Table 3) and in women aged 31–35 years from rural areas (from 6.89% in the 2013–2016 group to 0.69% in the 2019–2022 group).
3.2. Anti-Toxoplasma gondii IgG Antibodies
Demographic characteristics. Group 1 included 603 participants (34.00% rural), while Group 2 included 2901 participants (56.12% rural). The proportion of participants that were from rural areas increased with statistical significance from the 2013–2016 group to the 2019–2022 group (p < 0.001) (Table 4). Age distribution differed slightly between the groups.
Seroprevalence results. Both Group 1 and Group 2 had the highest seroprevalence in rural areas in women aged over 35 years (75.00% and 62.12%, respectively). The lowest seroprevalence in Group 1 was in women aged 31–35 from rural areas (13.79%), while in Group 2, it was in women from urban areas aged 26–30 (29.80%) (Table 5).
Overall, a slight increase in seroprevalence from 37.81% in 2013–2016 to 38.54% in 2019–2022 was observed. The seroprevalence showed a slight increase in urban areas compared with rural areas in Group 1 (from 36.59% to 38.44%), while in Group 2, the seroprevalence decreased from rural to urban areas (from 42.44% to 33.54%). In rural areas, there was a slight increase in IgG seroprevalence between the two time periods from 36.59% to 42.44% (p = 0.109), while in urban areas, we observed a slight decrease from 38.44% to 33.54% (p = 0.073).
In young women (< 20 years age group), we noticed a statistically significant decrease in IgG seroprevalence from 50.00% to 31.73% (p = 0.006) between the two time periods and in the 21–25 years age group in rural areas (p = 0.012). Interestingly, in women aged 31–35 years from rural areas, we observed an important increase in seroprevalence from 13.79% to 47.96% (p < 0.001) (Table 5 and Table 6).
3.3. Seroprevalence of Anti-T. gondii IgM Antibodies in Immunized Childbearing Age Women
In Group 1, the odds of having an anti-T. gondii IgM positive status was significantly higher in the anti-T. gondii IgG negative group compared to the anti-T. gondii IgG positive one (odds ratio = 10.81, 95% CI = 2.36–100.00, p < 0.001). In Group 2, the odds of anti-T. gondii IgM positivity was found to be significantly higher among women who tested negative for anti-T. gondii IgG (odds ratio = 40.77, 95% confidence interval = 6.65–1674.49, p < 0.001) (Table 7).
3.4. Maping of Toxoplasmosis Prevalence in Dolj County between 2019–2022
As our hospital from Craiova City tested childbearing-age women from various settlements in Dolj County, we analyzed the results based on the town of residence (Table 8, Figure 1).
The biggest seroprevalence was recorded in Sadova (57.57%) and Podari (58.97%) settlements, followed by Segarcea (45.83%), with a lower prevalence in Teasc (42.85%), Filiași (41.93%), Mârșani (40.90%), Desa. (40.90%) and Băilești (40.00%). The lowest prevalence was reported in Ciupercenii Noi (18.18%) (Table 8, Figure 1).
4. Discussion
The insights from our study contribute valuable information to the understanding of T. gondii epidemiology, highlighting the need for targeted interventions and continuous surveillance. Our findings reflect a dynamic pattern in the seroprevalence of T. gondii infection with notable shifts in its prevalence across different demographics. In general, antibody levels can vary significantly depending on the region and age group of the subjects [8,14]. Other studies reported significant differences between urban and rural populations in terms of their exposure to certain pathogens [27,28].
In our study, the number of women that tested for T. gondii infection markedly increased from 2013–2016 to 2019–2022 due to the increase in the medical information of patients and the progress in laboratory technology associated with a reduction in testing costs that have become affordable for the average pregnant women [29,30].
4.1. Anti-Toxoplasma gondii IgM Antibodies
In our study, the anti-T. gondii IgM antibodies’ seroprevalence was 2.32% in the 2013–2016 group and 1.06% in the 2019–2022 group, showing a marked decrease (Table 2). This could be due to an improvement in the socioeconomic status of the Romanian population [31].
Across Europe, there was also a reported decrease in seroprevalence in a study performed in Italy, from 1.60% in 2010 compared to 0.98% in 2007 [32]. A study performed in France reported a seroprevalence rate that declined from 0.75% in 1980 to 0.35% in 2000 and further to 0.24% in 2010 [33].
In Romania, a study from its Western region reported a slight increase in anti-T. gondii IgM seroprevalence from 2008–2010 (0.80%) to 2015–2018 (1.10%) [34]. A study performed in a big city in Northern Romania showed an IgM seroprevalence of 7.21% [35]. A possible explanation for this high prevalence is the higher testing rate for anti-T. gondii antibodies in the big cities, where access to testing is facile.
Our study found in the 2013–2016 group, the highest prevalence (5.26%) of anti-T. gondii IgM antibodies in the age group under 20 years, while in the 2019–2022 group, the highest prevalence (1.76%) was in the >35 years age group. A study from the Moldavia area of Romania detected an IgM seroprevalence of 7.35% in the 25–34 age group and 9.09% in the >35 years age group [35]. We can suppose that women over 35 years of age are more informed to perform all the necessary pregnancy screening tests, especially in recent years, resulting in a higher number of TORCH tests, as reported by other authors [36].
In both groups, the seroprevalence was higher in rural areas compared with urban areas, while a study from Brazil [27] reported no association between anti-T. gondii IgM seropositivity and rural residence or age.
Possible explanations for the declined seroprevalence in urban areas include decreased exposure to cats, higher socioeconomic status, modern and centralized sanitation systems, and the rigorous monitoring of water quality [10].
The seropositivity for IgM antibodies cannot be interpreted as an acute T. gondii infection because is well documented that IgM antibodies persist in individuals for a duration of 40 to 50 weeks after acute infection [37], while studies involving fertile women have reported a range of 25 to 65 weeks [17]. For congenitally infected neonates, the decay in IgM antibodies occurred more rapidly compared to adult individuals, although some remained positive for as long as 30 weeks postpartum [38].
4.2. Anti-Toxoplasma gondii IgG Antibodies
Our study showed a prevalence of anti-T. gondii IgG antibodies at 37.81% in the 2013–2016 group and 38.54% in the 2019–2022 group.
Various studies across Europe have examined the variability of anti-T. gondii IgG prevalence among pregnant women populations [13,16,17,18,19,20,21,22] from 8.2% in Switzerland [24] to 59% in Germany [23]. A study on pregnant women performed in Iraq found a total IgG seroprevalence of 33.7%, and the maximum prevalence (64%) was recorded in the 21–30 years of age group [28].
Information regarding the prevalence of T. gondii in the human population in Romania is scarce [8]. Most serological surveys rely on convenience samples [9]. One exception is a study performed by Coroiu et al. in 2009 [39], which used a stratified sampling strategy from the general population located in 11 counties from central and North-West Romania (4.6 million people). From the 1155 samples tested, anti-T. gondii IgG antibodies were present in 59.48%, with a higher prevalence in rural areas (63.68%) vs. urban areas (55.12%), without significant gender differences but with an estimated annual risk in young people of 4.5% [39].
Research from Western Romania indicated a decrease in T. gondii infections by approximately five percentage points (from 43.79% to 38.81%) among pregnant women over ten years between 2008–2010 and 2015–2018 [40].
Another investigation in Western Romania reported a prevalence of 64.8% in 2015 [41]. Subsequent research during 2020 and 2022 revealed prevalence rates ranging between 36.48% and 55.8% in Western Romania [8,34,39,40,41,42,43,44]. The lowest prevalence was observed in a study from the Bihor area (Western Romania) [45], which reported a rate of 25.4% among pregnant women who sought consultation at infectious disease clinics. Interestingly, in childbearing-age women from Western Romania, another study from the same area [42] also indicated a relatively low prevalence of 36.48% compared with another study from the Banat (Western Romania) area, which found a prevalence of 41.16% [46].
A study on pregnant women from Northern Romania [35] showed a prevalence of IgGs of 32.83% in the 25–34 age group and 37.83% in the >35 years age group, while in our study, the highest prevalence was recorded in the <20 years age group (50.00%) and in the over 35 years of age group it was 35.19%. Another study from Western Romania supported our research showing that the highest prevalence of anti-T. gondii IgG antibodies were in women aged between 20 and 30 years [39].
Regarding the area of residence, in Group 1, our results showed similar seroprevalences in rural and urban areas, while in Group 2, the seroprevalence was higher in rural areas. Supporting our results, a study from Poland [47] found that women living in rural areas had three times higher odds of being infected with T. gondii compared with urban areas. Another study from Brazil also found an OR of 3.46 for anti-T. gondii IgG in rural vs. urban areas [27].
The differences in seroprevalence between studies from various regions could be explained by the heterogeneity of the studied groups. There are differences in population structure by age and area of residence, as well as other factors like education level that influence the prevalence of toxoplasmosis. Additionally, the patient populations addressing private centers and public hospitals (where testing is free) are different in terms of demographic and socioeconomic factors [48].
4.3. Seroprevalence of Anti-T. gondii IgM Antibodies in Immunized Childbearing Age Women
Our findings suggest that anti-T. gondii IgG status is a significant predictor of anti-T. gondii IgM status among women, and screening for anti-T. gondii IgG might be useful in identifying women at risk for T. gondii infection during pregnancy. Therefore, IgG-negative women should be screened and re-screened for T. gondii infection. We cannot, however, generalize that the positive test for IgG contraindicates the IgM test because there is a non-negligible possibility for IgG seropositive women to also have anti-T. gondii IgM antibodies [37]. A definitive diagnosis can only be conducted through the IgG avidity test or PCR test for CMV DNA [48].
These results bear significant implications for devising public health policies and interventions, especially within communities where the prevalence of T. gondii is relatively low. Additionally, data from our study enhanced the existing epidemiological comprehension of T. gondii in pregnant women, paving the way for more informed and targeted preventative and treatment measures against this infection.
4.4. Maping of Toxoplasmosis Prevalence in Dolj County between 2019–2022
There was a notably high seroprevalence of anti-T. gondii IgG antibodies in fertile women tested from various settlements in Dolj county, South-West Romania. Interestingly, the toxoplasmosis prevalence was higher in the settlements near Craiova city than in the city of Craiova, which could be explained by easy access to Craiova hospital due to short distance bus lines.
The higher seroprevalence in the rural areas around Craiova might be due to factors specific to rural areas [28,47], such as the higher number of cats per household, lower adherence to hygiene measures, and a lower level of education [49]. As women from rural areas are at a higher risk for T. gondii infection, targeted intervention strategies should be considered in these areas, including health education programs about toxoplasmosis risk factors and prevention methods.
Studies have demonstrated a positive correlation between toxoplasmosis prevalence and factors such as drinking unfiltered water and contact with animals and soil [50,51,52,53]. This implies that people, especially farm workers in rural areas, are more exposed to sources of toxoplasmosis infection [27,51,53].
4.4.1. Limitations
The present study has several limitations. Our sample was a convenience sample; specifically, we took all women addressing for the serological testing of anti-T. gondii antibodies in a single center. Although most of the women performed both IgM and IgG tests, some had tested either only the IgG or IgM antibodies, which explained the difference between the number of women tested for IgM and IgG. We did not analyze all the factors that could increase the risk of acquiring toxoplasmosis because we did not administer questionnaires to these women. We only analyzed the demographic factors that could influence the risk of acquiring toxoplasmosis. For example, several studies showed that eating raw or undercooked meat was a significant risk factor [28,47], and there probably exist other risk factors that can confound the group differences we found.
In our study, we observed a shift toward more participants from rural areas in the second time period, which could have implications for the generalization of this study’s findings. It is also worth noting that other factors, such as changes in recruitment methods or eligibility criteria, could have influenced these results; therefore, it is important to consider the context and limitations of the study when interpreting these findings [36].
4.4.2. Future Directions
Addressing the high prevalence of toxoplasmosis in childbearing-age women in Dolj County requires a multifaceted approach that includes increased screening, targeted health education, the promotion of behavioral changes, and preconception counseling.
The fact that the seroprevalence of anti-T. gondii IgG antibodies were rather low could also be regarded as there is a high proportion of women at risk for acute toxoplasmic infection.
Further research is needed to better understand the factors influencing the prevalence of toxoplasmosis and to develop effective strategies for prevention and control in different regions and populations, particularly in populations at a higher risk of infection, such as pregnant women.
5. Conclusions
The seroprevalence of anti-T. gondii IgM antibodies in tested childbearing-age women, including either positive or negative for anti-T. gondii IgG antibodies showed a marked decrease from 2013–2016 to 2019–2022, which is more significant in urban areas and in 21–25 years and 31–35 years age groups. We found that anti-T. gondii IgG immunization is a significant protection factor against toxoplasmosis infection and was detected by anti-T. gondii IgM in women; therefore, screening for anti-T. gondii IgG might be useful in identifying women at risk for T. gondii infection.
Conversely, the seroprevalence of anti-T. gondii anti-IgG antibodies seroprevalence showed a slight increase from 37.81% to 38.54%. This increase was pronounced in rural areas (the highest was in the 31–35 age group), while in urban areas, we recorded a decrease.
In Dolj County, South-West Romania, the high prevalence of toxoplasmosis childbearing women suggests an urgent need to enhance screening and toxoplasmosis awareness. The notably higher prevalence of toxoplasmosis in smaller settlements around Craiova city compared to the city itself suggests that fertile women in rural areas are at higher risk.
This study also underscores the necessity for further investigation to augment our understanding of the factors that influence the prevalence of toxoplasmosis across various regions and populations. This could aid in the formulation of efficacious strategies for the prevention and control of this infection.
Author Contributions
Conceptualization, C.L.R., O.M.Z. and D.G.I.; methodology, O.M.Z. and A.C.S.; software, O.M.Z.; validation, D.G.I.; formal analysis, C.L.R. and O.M.Z.; investigation, C.L.R., L.G. and L.D.; resources, M.B. and D.G.I.; data curation, C.L.R. and O.M.Z.; writing—original draft preparation, C.L.R., O.M.Z. and A.N.; writing—review and editing, C.L.R., O.M.Z. and D.G.I.; visualization, A.N.; supervision, D.G.I. All authors have read and agreed to the published version of the manuscript.
Funding
The Article Processing Charges were funded by the University of Medicine and Pharmacy of Craiova, Romania.
Institutional Review Board Statement
This study was approved by the Committee of Ethics and Academic and Scientific Deontology, Craiova, Romania (approval no. 84/16.09.2020). The access of the database for the purpose of this study was approved by the Ethics Committee of Clinical County Emergency Hospital of Craiova, Romania.
Informed Consent Statement
Because we are a teaching hospital, all patients admitted in our hospital signed a written consent by which they agree that their medical data can be used in scientific studies.
Data Availability Statement
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to patient personal data protection policy of the University and Hospital.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Ybañez, R.H.D.; Ybañez, A.P.; Nishikawa, Y. Review on the Current Trends of Toxoplasmosis Serodiagnosis in Humans. Front. Cell Infect. Microbiol. 2020, 10, 204. [Google Scholar] [CrossRef] [PubMed]
- Helmy, Y.A.; El-Adawy, H.; Abdelwhab, E.M. A Comprehensive Review of Common Bacterial, Parasitic and Viral Zoonoses at the Human-Animal Interface in Egypt. Pathogens 2017, 6, 33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Robert-Gangneux, F.; Dardé, M.L. Epidemiology of and Diagnostic Strategies for Toxoplasmosis. Clin. Microbiol. Rev. 2012, 25, 264–296. [Google Scholar] [CrossRef] [Green Version]
- Madireddy, S.; Rivas Chacon, E.D.; Mangat, R. Toxoplasmosis; StatPearls: Orlando, FL, USA, 2023. [Google Scholar]
- Wang, Z.D.; Liu, H.H.; Ma, Z.X.; Ma, H.Y.; Li, Z.Y.; Yang, Z.B.; Zhu, X.Q.; Xu, B.; Wei, F.; Liu, Q. Toxoplasma Gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis. Front. Microbiol. 2017, 8, 389. [Google Scholar] [CrossRef] [Green Version]
- Marcu, E.A.; Dinescu, S.N.; Pădureanu, V.; Dumitrescu, F.; Diaconu, R. Perinatal Exposure to HIV Infection: The Experience of Craiova Regional Centre, Romania. Healthcare 2022, 10, 308. [Google Scholar] [CrossRef]
- Cambrea, S.C.; Marcu, E.A.; Cucli, E.; Badiu, D.; Penciu, R.; Petcu, C.L.; Dumea, E.; Halichidis, S.; Pazara, L.; Mihai, C.M.; et al. Clinical and Biological Risk Factors Associated with Increased Mother-to-Child Transmission of HIV in Two South-East HIV-AIDS Regional Centers in Romania. Medicina 2022, 58, 275. [Google Scholar] [CrossRef]
- Dubey, J.P.; Hotea, I.; Olariu, T.R.; Jones, J.L.; Dǎrǎbuş, G. Epidemiological Review of Toxoplasmosis in Humans and Animals in Romania. Parasitology 2014, 141, 311–325. [Google Scholar] [CrossRef]
- Kota, A.S.; Shabbir, N. Congenital Toxoplasmosis; StatPearls: Orlando, FL, USA, 2023. [Google Scholar]
- Donadono, V.; Saccone, G.; Maruotti, G.M.; Berghella, V.; Migliorini, S.; Esposito, G.; Sirico, A.; Tagliaferri, S.; Ward, A.; Mazzarelli, L.L.; et al. Incidence of Toxoplasmosis in Pregnancy in Campania: A Population-Based Study on Screening, Treatment, and Outcome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2019, 240, 316–321. [Google Scholar] [CrossRef] [PubMed]
- Donadono, V.; Saccone, G.; Sarno, L.; Esposito, G.; Mazzarelli, L.L.; Sirico, A.; Guida, M.; Martinelli, P.; Zullo, F.; Maruotti, G.M. Association between Lymphadenopathy after Toxoplasmosis Seroconversion in Pregnancy and Risk of Congenital Infection. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 45–51. [Google Scholar] [CrossRef]
- Neamtu, S.D.; Braila, A.D.; Braila, M.; Brujan, I.; Dumitrescu, F.; Vasile, M.; Mocanu, C.; Neamtu, C. Clinical-Statistical Study of the Patients Who Suffer from Infections Which Are Brought about Factors of Torch Complex. Craiova Medicala 2006, 8, 75–79. [Google Scholar]
- Saadatnia, G.; Golkar, M. A Review on Human Toxoplasmosis. Scand. J. Infect. Dis. 2012, 44, 805–814. [Google Scholar] [CrossRef]
- Tenter, A.M.; Heckeroth, A.R.; Weiss, L.M. Toxoplasma Gondii: From Animals to Humans. Int. J. Parasitol. 2000, 30, 1217–1258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meerburg, B.G.; Kijlstra, A. Changing Climate-Changing Pathogens: Toxoplasma Gondii in North-Western Europe. Parasitol. Res. 2009, 105, 17–24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carme, B.; Lenne, E.; Tirard, V.; Hayette, M.P.; Gondry, J. Etude Épidémiologique de La Toxoplasmose Chez Les Femmes Enceintes à Amiens (Picardie). Nécessité d’une Enquête Nationale. Med. Mal. Infect. 1994, 24, 1271–1273. [Google Scholar] [CrossRef]
- Fricker-Hidalgo, H.; Bailly, S.; Brenier-Pinchart, M.P.; Dard, C.; Jean, D.; Coston, A.L.; Garnaud, C.; Pelloux, H. How to Estimate Time of Infection with Toxoplasma Gondii in Pregnant Women. Use of Specific IgG and IgM Kinetics by 7 Techniques on 691 Sera. Diagn. Microbiol. Infect. Dis. 2020, 96, 114987. [Google Scholar] [CrossRef]
- Olariu, T.; Cretu, O.; Darabus, G.; Marincu, I.; Jurovits, O.; Erdelean, V.; Tirnea, L.; Neghina, R.; Iacobiciu, I.; Petrescu, C.; et al. Screening for Toxoplasma Gondii Antibodies among Women of Childbearing Age, in Timis County, Romania. In Proceedings of the 13th International Congress of Infectious Diseases, Kuala Lumpur, Malaysia, 19–22 June 2008. [Google Scholar]
- Pappas, G.; Roussos, N.; Falagas, M.E. Toxoplasmosis Snapshots: Global Status of Toxoplasma Gondii Seroprevalence and Implications for Pregnancy and Congenital Toxoplasmosis. Int. J. Parasitol. 2009, 39, 1385–1394. [Google Scholar] [CrossRef]
- Puccio, G.; Cajozzo, C.; Canduscio, L.A.; Cino, L.; Romano, A.; Schimmenti, M.G.; Giuffrè, M.; Corsello, G. Epidemiology of Toxoplasma and CMV Serology and of GBS Colonization in Pregnancy and Neonatal Outcome in a Sicilian Population. Ital. J. Pediatr. 2014, 40, 23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stopić, M.; Štajner, T.; Marković-Denić, L.; Nikolić, V.; Djilas, I.; Jovanović Srzentić, S.; Djurković-Djaković, O.; Bobić, B. Epidemiology of Toxoplasmosis in SERBIA: A Cross-Sectional Study on Blood Donors. Microorganisms 2022, 10, 492. [Google Scholar] [CrossRef]
- Torgerson, P.R.; Mastroiacovo, P. The Global Burden of Congenital Toxoplasmosis: A Systematic Review. Bull. World Health Organ. 2013, 91, 501–508. [Google Scholar] [CrossRef]
- Fiedle, K.; Hülsse, C.; Straube, W.; Briese, V. Toxoplasmosis-Antibody Seroprevalence in Mecklenburg-Western Pomerania. Zentralbl. Gynakol. 1999, 121, 239–243. [Google Scholar]
- Zufferey, J.; Di Mito, C.; Auckenthaler, R. Evaluation of the New Vidia Toxoplasmosis IgG and IgM Assays in Women of Childbearing Age. Clin. Microbiol. Infect. 2007, 13 (Suppl. S1), 124. [Google Scholar] [CrossRef]
- Epelboin, L.; Abboud, P.; Abdelmoumen, K.; About, F.; Adenis, A.; Blaise, T.; Blaizot, R.; Bonifay, T.; Bourne-Watrin, M.; Boutrou, M.; et al. Overview of Infectious and Non-Infectious Diseases in French Guiana in 2022. Med. Trop. Sante Int. 2023, 3, mtsi-v3i1. [Google Scholar] [CrossRef]
- Jones, J.L.; Kruszon-Moran, D.; Elder, S.; Rivera, H.N.; Press, C.; Montoya, J.G.; McQuillan, G.M. Toxoplasma Gondii Infection in the United States, 2011–2014. Am. J. Trop. Med. Hyg. 2018, 98, 551–557. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Antinarelli, L.M.R.; Silva, M.R.; Guimarães, R.J.D.P.S.E.; Terror, M.S.; Lima, P.E.; Ishii, J.D.S.C.; Muniz, P.F.; Coimbra, E.S. Rural Residence Remains a Risk Factor for Toxoplasma Infection among Pregnant Women in a Highly Urbanized Brazilian Area: A Robust Cross-Sectional Study. Trans. R. Soc. Trop. Med. Hyg. 2021, 115, 896–903. [Google Scholar] [CrossRef]
- Ameer, J.K.A.; Aamer, N.R. Comparisons of Toxoplasma Gondii Prevalence in Rural and Urban Areas of Al-Najaf Province of Iraq Using Serological Methods. Arch. Razi Inst. 2021, 76, 1695. [Google Scholar] [CrossRef]
- World Health Organization. Romania: Health System Review 2016; Health Systems in Transition; World Health Organization: Geneva, Switzerland, 2016; Volume 18. [Google Scholar]
- Purcărea, V.L.; Coculescu, B.I.; Coculescu, E.C. Improving the Quality of Health Care in the Romanian Public Health System—A Priority in the Reform Process. J. Med. Life 2015, 8, 166. [Google Scholar] [PubMed]
- European Economic and Social Committee. The Economic and Social Situation in Romania; European Economic and Social Committee: Brussels, Belgium, 2015. [Google Scholar]
- Mosti, M.; Pinto, B.; Giromella, A.; Fabiani, S.; Cristofani, R.; Panichi, M.; Bruschi, F. A 4-Year Evaluation of Toxoplasmosis Seroprevalence in the General Population and in Women of Reproductive Age in Central Italy. Epidemiol. Infect. 2013, 141, 2192–2195. [Google Scholar] [CrossRef]
- Sawers, L.; Wallon, M.; Mandelbrot, L.; Villena, I.; Stillwaggon, E.; Kieffer, F. Prevention of Congenital Toxoplasmosis in France Using Prenatal Screening: A Decision-Analytic Economic Model. PLoS ONE 2022, 17, e0273781. [Google Scholar] [CrossRef]
- Mocanu, A.; Gorun, F.; Ciohat, I.; Navolan, D.; Malita, D.; Vilibic-Cavlek, T.; Dahma, G.; Neamtu, R.; Popescu, D.; Cioca, A.; et al. Simultaneous Seroprevalence to Toxoplasma Gondii, Cytomegalovirus and Rubella Virus in Childbearing Women from Western Romania. Medicina 2021, 57, 927. [Google Scholar] [CrossRef]
- Ivănescu, L.; Mătiuț, S.; Martinescu, G.; Bălbărău, A.; Miron, L. Toxoplasmosis-a Disease with High Epidemiological Risk in Humans and Animals. Sci. Pap. J. Vet. Ser. 2021, 64, 61–71. [Google Scholar]
- Cornu, C.; Bissery, A.; Malbos, C.; Garwig, R.; Cocherel, C.; Ecochard, R.; Peyron, F.; Wallon, M. Factors Affecting the Adherence to an Antenatal Screening Programme: An Experience with Toxoplasmosis Screening in France. Eurosurveillance 2009, 14, 21–25. [Google Scholar]
- Vargas-Villavicencio, J.A.; Cañedo-Solares, I.; Correa, D. Anti- Toxoplasma Gondii IgM Long Persistence: What Are the Underlying Mechanisms? Microorganisms 2022, 10, 1659. [Google Scholar] [CrossRef]
- Lago, E.G.; Oliveira, A.P.; Bender, A.L. Presence and Duration of Anti-Toxoplasma Gondii Immunoglobulin M in Infants with Congenital Toxoplasmosis. J. Pediatr. 2014, 90, 363–369. [Google Scholar] [CrossRef] [Green Version]
- Coroiu, Z.; Radu, R.; Molnar, A.; Bele, J. Seroprevalence of Anti Toxoplasma Gondii Antibodies in the Healthy Population from North-Western and Central Romania. Sci. Parasitol. 2009, 1, 37–42. [Google Scholar]
- Motoi, S.; Navolan, D.B.; Malita, D.; Ciohat, I.; Nemescu, D.; Manciuc, C.; Gorun, F.; Vilibic-Cavlek, T.; Boda, D.; Craina, M.; et al. A Decreasing Trend in Toxoplasma Gondii Seroprevalence among Pregnant Women in Romania—Results of a Large Scale Study. Exp. Ther. Med. 2020, 20, 3536–3540. [Google Scholar] [CrossRef] [PubMed]
- Olariu, T.R.; Petrescu, C.; Darabus, G.; Lighezan, R.; Mazilu, O. Seroprevalence of Toxoplasma Gondii in Western Romania. Infect. Dis. 2015, 47, 580–583. [Google Scholar] [CrossRef]
- Mihu, A.G.; Micle, O.; Lupu, M.A.; Olariu, T.R. Seroprevalence of Toxoplasma Gondii in Females Aged 15–45 Years from Bihor County, Western Romania. Vector Borne Zoonotic Dis. 2022, 22, 195–198. [Google Scholar] [CrossRef]
- Lupu, M.A.; Lighezan, R.; Paduraru, A.A.; Dragomir, A.; Pavel, R.; Grada, S.; Mihu, A.G.; Ursoniu, S.; Olariu, T.R. Seroepidemiology of Toxoplasma Gondii Infection in Blood Donors from Western Romania. Microorganisms 2022, 10, 973. [Google Scholar] [CrossRef]
- Olariu, T.R.; Ursoniu, S.; Hotea, I.; Dumitrascu, V.; Anastasiu, D.; Lupu, M.A. Seroprevalence and Risk Factors of Toxoplasma Gondii Infection in Pregnant Women from Western Romania. Vector-Borne Zoonotic Dis. 2020, 20, 763–767. [Google Scholar] [CrossRef] [PubMed]
- Csep, A.; Vaida, L.L.; Negruțiu, B.-M.; Todor, B.I.; Judea-Pusta, C.T.; Buhaș, C.; Sava, C. Research on Demographic, Clinical and Paraclinical Aspects in Pregnant Women Infected with Toxoplasma Gondii. Exp. Ther. Med. 2022, 23, 123. [Google Scholar] [CrossRef] [PubMed]
- Mihu, A.G.; Balta, C.; Marti, D.T.; Paduraru, A.A.; Lupu, M.A.; Olariu, T.R. Seroprevalence of Toxoplasma Gondii Infection among Women of Childbearing Age in an Endemic Region of Romania, 2016–2018. Parasite 2020, 27, 59. [Google Scholar] [CrossRef] [PubMed]
- Bieńkowski, C.; Aniszewska, M.; Kowalczyk, M.; Popielska, J.; Zawadka, K.; Ołdakowska, A.; Pokorska-śpiewak, M. Analysis of Preventable Risk Factors for Toxoplasma Gondii Infection in Pregnant Women: Case-Control Study. J. Clin. Med. 2022, 11, 1105. [Google Scholar] [CrossRef] [PubMed]
- Mihu, A.G.; Lupu, M.A.; Nesiu, A.; Marti, D.T.; Olariu, T.R. Screening for the Detection of Toxoplasma Gondii IgG, IgM and IgA in Females of Reproductive Age from Western Romania. Life 2022, 12, 1771. [Google Scholar] [CrossRef] [PubMed]
- Rugină, S.; Dumitru, I.M.; Dumitru, E. Toxoplasmosis in Immunocompetent and Immunocompromised Population of Constanţa, Romania. ARS Medica Tomitana 2015, 21, 22–26. [Google Scholar] [CrossRef]
- Nash, J.Q.; Chissel, S.; Jones, J.; Warburton, F.; Verlander, N.Q. Risk Factors for Toxoplasmosis in Pregnant Women in Kent, United Kingdom. Epidemiol. Infect. 2005, 133, 475–483. [Google Scholar] [CrossRef]
- Retmanasari, A.; Widartono, B.S.; Wijayanti, M.A.; Artama, W.T. Prevalence and Risk Factors for Toxoplasmosis in Middle Java, Indonesia. Ecohealth 2016, 14, 162–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garcia Bahia-Oliveira, L.M.; Jones, J.L.; Azevedo-Silva, J.; Alves, C.C.F.; Oréfice, F.; Addiss, D.G. Highly Endemic, Waterborne Toxoplasmosis in North Rio de Janeiro State, Brazil. Emerg. Infect. Dis. 2003, 9, 55–62. [Google Scholar] [CrossRef]
- Mohamed, K.; Kodym, P.; Malý, M.; Rayah, I.E. Environmental and Food Habitat Risk Factors Associated with Toxoplasma Gondii Infection in Rural Women in Sudan. Int. J. Curr. Microbiol. Appl. Sci. 2014, 3, 208–222. [Google Scholar]
Figure 1.
IgG anti-T. gondii seroprevalence in childbearing women—spread in Dolj county, Romania 2019–2022.
Figure 1.
IgG anti-T. gondii seroprevalence in childbearing women—spread in Dolj county, Romania 2019–2022.
Table 1.
Demographic characteristics of the fertile age women tested for IgM anti-T. gondii antibodies.
Table 1.
Demographic characteristics of the fertile age women tested for IgM anti-T. gondii antibodies.
| Group 1 n = 602 | Group 2 n = 3014 | p | |
|---|---|---|---|
| Area of residence (n/%) | |||
| Rural | 206 (34.21%) | 1704 (56.54) | <0.001 * |
| Urban | 396 (65.79) | 1310 (43.46%) | |
| Age (years) | 27.79 (5.46) | 27.62 (6.24) | 0.537 |
*: Statistical significant result.
Table 2.
Comparative seroprevalence of anti-T. gondii IgM antibodies between the two groups stratified by the area of residence and age group.
Table 2.
Comparative seroprevalence of anti-T. gondii IgM antibodies between the two groups stratified by the area of residence and age group.
| Variable | Group 1 2013–2016 (n = 602) | Group 2 2019–2022 (n = 3014) | p Value |
|---|---|---|---|
| TOTAL PREVALENCE | 14/602 (2.32%) | 32/3014 (1.06%) | 0.012 * |
| AREA OF RESIDENCE | |||
| Rural | 6/206 (2.91%) | 24/1704 (1.40%) | 0.099 |
| Urban | 8/396 (2.02%) | 8/1310 (0.61%) | 0.011 * |
| AGE GROUP | |||
| <20 years | 3/57 (5.26%) | 7/436 (1.60%) | 0.065 |
| 21–25 years | 3/145 (2.06%) | 5/735 (0.68%) | 0.109 |
| 26–30 years | 4/239 (1.67%) | 10/847 (1.18%) | 0.553 |
| 31–35 years | 2/105 (1.90%) | 4/656 (0.60%) | 0.160 |
| >35 years | 2/56 (3.57%) | 6/340 (1.76%) | 0.372 |
| AREA OF RESIDENCE AND AGE GROUP | |||
| Rural, <20 years | 1/37 (2.70%) | 6/333 (1.80%) | 0.703 |
| Rural, 21–25 years | 1/61 (1.63%) | 4/509 (0.78%) | 0.500 |
| Rural, 26–30 years | 1/67 (1.49%) | 7/433 (1.61%) | 0.942 |
| Rural, 31–35 years | 2/29 (6.89%) | 2/287 (0.69%) | 0.004 * |
| Rural, >35 years | 1/12 (8.33%) | 5/142 (3.52%) | 0.408 |
| Urban, <20 years | 2/20 (10.00%) | 1/103 (0.97%) | 0.017 * |
| Urban, 21–25 years | 2/84 (2.38%) | 1/226 (0.74%) | 0.235 |
| Urban, 26–30 years | 3/172 (1.74%) | 3/414 (0.72%) | 0.263 |
| Urban, 31–35 years | 0/76 (0%) | 2/369 (0.54%) | 0.521 |
| Urban, >35 years | 1/44 (2.27%) | 1/198 (0.50%) | 0.234 |
*: Statistical significant result.
Table 3.
Seroprevalence of anti-T. gondii IgM antibodies in the two groups according to demographic factors.
Table 3.
Seroprevalence of anti-T. gondii IgM antibodies in the two groups according to demographic factors.
| Group 1 (2013–2016) (n = 602) | Group 2 (2019–2022) (n = 3014) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area of Residence | Area of Residence | |||||||||||||||||
| Rural | Urban | Total | Rural | Urban | Total | |||||||||||||
| Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | |
| Age group | ||||||||||||||||||
| <20 years | ||||||||||||||||||
| No. | 36 | 1 | 37 | 18 | 2 | 20 | 54 | 3 | 57 | 327 | 6 | 333 | 102 | 1 | 103 | 429 | 7 | 436 |
| % | 97.29 | 2.70 | 100 | 90.0 | 10.0 | 100 | 94.73 | 5.26 | 100 | 98.19 | 1.80 | 100 | 99.02 | 0.97 | 100 | 98.39 | 1.60 | 100 |
| 21–25 years | ||||||||||||||||||
| No. | 60 | 1 | 61 | 82 | 2 | 84 | 142 | 3 | 145 | 505 | 4 | 509 | 225 | 1 | 226 | 730 | 5 | 735 |
| % | 98.36 | 1.63 | 100 | 97.61 | 2.38 | 100 | 97.93 | 2.06 | 100 | 99.21 | 0.78 | 100 | 99.55 | 0.44 | 100 | 99.31 | 0.68 | 100 |
| 26–30 years | ||||||||||||||||||
| No. | 66 | 1 | 67 | 169 | 3 | 172 | 235 | 4 | 239 | 426 | 7 | 433 | 411 | 3 | 414 | 837 | 10 | 847 |
| % | 98.50 | 1.49 | 100 | 98.25 | 1.74 | 100 | 98.32 | 1.67 | 100 | 98.38 | 1.61 | 100 | 99.27 | 0.72 | 100 | 98.81 | 1.18 | 100 |
| 31–35 years | ||||||||||||||||||
| No. | 27 | 2 | 29 | 76 | 0 | 76 | 103 | 2 | 105 | 285 | 2 | 287 | 367 | 2 | 369 | 652 | 4 | 656 |
| % | 93.10 | 6.89 | 100 | 100 | 0 | 100 | 98.09 | 1.90 | 100 | 99.30 | 0.69 | 100 | 99.45 | 0.54 | 100 | 99.39 | 0.60 | 100 |
| >35 years | ||||||||||||||||||
| No. | 11 | 1 | 12 | 43 | 1 | 44 | 54 | 2 | 56 | 137 | 5 | 142 | 197 | 1 | 198 | 334 | 6 | 340 |
| % | 91.66 | 8.33 | 100 | 97.72 | 2.27 | 100 | 96.42 | 3.57 | 100 | 96.47 | 3.52 | 100 | 99.49 | 0.50 | 100 | 98.23 | 1.76 | 100 |
| Total | ||||||||||||||||||
| No. | 200 | 6 | 206 | 388 | 8 | 396 | 588 | 14 | 602 | 1680 | 24 | 1704 | 1302 | 8 | 1310 | 2982 | 32 | 3014 |
| % | 97.08 | 2.91 | 100 | 97.97 | 2.02 | 100 | 97.67 | 2.32 | 100.00 | 98.59 | 1.40 | 100 | 99.38 | 0.61 | 100 | 98.94 | 1.06 | 100.00 |
Table 4.
Demographic characteristics of the female subjects tested for IgG anti-T. gondii antibodies.
Table 4.
Demographic characteristics of the female subjects tested for IgG anti-T. gondii antibodies.
| Group 1 n = 603 | Group 2 n = 2901 | p | |
|---|---|---|---|
| Area of residence (n/%) | |||
| Rural | 205 (34.00%) | 1628 (56.12%) | <0.001 * |
| Urban | 398 (66.00%) | 1273 (43.88%) | |
| Age (years) | 27.75 (5.42) | 27.67 (6.23) | 0.770 |
*: Statistical significant result.
Table 5.
Comparative seroprevalence of anti-T. gondii IgG antibodies between the two groups, stratified by area of residence and age group.
Table 5.
Comparative seroprevalence of anti-T. gondii IgG antibodies between the two groups, stratified by area of residence and age group.
| Variable | Group 1 2013–2016 (n = 603) | Group 2 2019–2022 (n = 2901) | p Value |
|---|---|---|---|
| TOTAL PREVALENCE | 228/603 (37.81%) | 1118/2901 (38.54%) | 0.737 |
| AREA OF RESIDENCE | |||
| RURAL | 75/205 (36.59%) | 691/1628 (42.44%) | 0.109 |
| URBAN | 153/398 (38.44%) | 427/1273 (33.54%) | 0.073 |
| AGE GROUP | |||
| <20 YEARS | 29/58 (50.00%) | 132/416 (31.73%) | 0.006 * |
| 21–25 YEARS | 56/142 (39.44%) | 273/714 (38.24%) | 0.788 |
| 26–30 YEARS | 92/244 (37.70%) | 313/824 (37.99%) | 0.935 |
| 31–35 YEARS | 32/105 (30.48%) | 245/628 (39.01%) | 0.095 |
| >35 YEARS | 19/54 (35.19%) | 155/319 (48.59%) | 0.068 |
| AREA OF RESIDENCE AND AGE GROUP | |||
| RURAL, <20 YEARS | 19/37 (51.35) | 99/315 (31.43) | 0.015 * |
| RURAL, 21–25 YEARS | 17/59 (28.81%) | 189/494 (38.26%) | 0.012 * |
| RURAL, 26–30 YEARS | 26/68 (38.24%) | 192/418 (45.93%) | 0.237 |
| RURAL, 31–35 YEARS | 4/29 (13.79%) | 129/269 (47.96%) | <0.001 * |
| RURAL, >35 YEARS | 9/12 (75.00%) | 82/132 (62.12%) | 0.376 |
| URBAN, <20 YEARS | 10/21 (47.62%) | 33/101 (32.67%) | 0.192 |
| URBAN, 21–25 YEARS | 39/83 (46.99%) | 84/220 (38.18%) | 0.164 |
| URBAN, 26–30 YEARS | 66/176 (37.50%) | 121/406 (29.80%) | 0.068 |
| URBAN, 31–35 YEARS | 28/76 (36.84%) | 116/359 (32.31%) | 0.446 |
| URBAN, >35 YEARS | 10/42 (23.81%) | 73/187 (39.04%) | 0.063 |
*: Statistical significant result.
Table 6.
Seroprevalence of anti-T. gondii IgG antibodies in the two groups according to demographic factors.
Table 6.
Seroprevalence of anti-T. gondii IgG antibodies in the two groups according to demographic factors.
| Group 1 (2013–2016) (n = 603) | Group 2 (2019–2022) (n = 2901) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area of Residence | Area of Residence | |||||||||||||||||
| Rural | Urban | Total | Rural | Urban | Total | |||||||||||||
| Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | Neg. | Pos. | Total | |
| Age group | ||||||||||||||||||
| <20 years | ||||||||||||||||||
| No. | 18 | 19 | 37 | 11 | 10 | 21 | 29 | 29 | 58 | 216 | 99 | 315 | 68 | 33 | 101 | 284 | 132 | 416 |
| % | 48.65 | 51.35 | 100.00 | 52.38 | 47.62 | 100.00 | 50.00 | 50.00 | 100.00 | 68.57 | 31.43 | 100.00 | 67.33 | 32.67 | 100.00 | 68.27 | 31.73 | 100.00 |
| 21–25 years | ||||||||||||||||||
| No. | 42 | 17 | 59 | 44 | 39 | 83 | 86 | 56 | 142 | 305 | 189 | 494 | 136 | 84 | 220 | 441 | 273 | 714 |
| % | 71.19 | 28.81 | 100.00 | 53.01 | 46.99 | 100.00 | 60.56 | 39.44 | 100.00 | 61.74 | 38.26 | 100.00 | 61.82 | 38.18 | 100.00 | 61.76 | 38.24 | 100.00 |
| 26–30 years | ||||||||||||||||||
| No. | 42 | 26 | 68 | 110 | 66 | 176 | 152 | 92 | 244 | 226 | 192 | 418 | 285 | 121 | 406 | 511 | 313 | 824 |
| % | 61.76 | 38.24 | 100.00 | 62.50 | 37.50 | 100.00 | 62.30 | 37.70 | 100.00 | 54.07 | 45.93 | 100.00 | 70.20 | 29.80 | 100.00 | 62.01 | 37.99 | 100.00 |
| 31–35 years | ||||||||||||||||||
| No. | 25 | 4 | 29 | 48 | 28 | 76 | 73 | 32 | 105 | 140 | 129 | 269 | 243 | 116 | 359 | 383 | 245 | 628 |
| % | 86.21 | 13.79 | 100.00 | 63.16 | 36.84 | 100.00 | 69.52 | 30.48 | 100.00 | 52.04 | 47.96 | 100.00 | 67.69 | 32.31 | 100.00 | 60.99 | 39.01 | 100.00 |
| >35 years | ||||||||||||||||||
| No. | 3 | 9 | 12 | 32 | 10 | 42 | 35 | 19 | 54 | 50 | 82 | 132 | 114 | 73 | 187 | 164 | 155 | 319 |
| % | 25.00 | 75.00 | 100.00 | 76.19 | 23.81 | 100.00 | 64.81 | 35.19 | 100.00 | 37.88 | 62.12 | 100.00 | 60.96 | 39.04 | 100.00 | 51.41 | 48.59 | 100.00 |
| Total | ||||||||||||||||||
| No. | 130 | 75 | 205 | 245 | 153 | 398 | 375 | 228 | 603 | 937 | 691 | 1628 | 846 | 427 | 1273 | 1783 | 1118 | 2901 |
| % | 63.41 | 36.59 | 100.00 | 61.56 | 38.44 | 100.00 | 62.19 | 37.81 | 100.00 | 57.56 | 42.44 | 100.00 | 66.46 | 33.54 | 100.00 | 61.46 | 38.54 | 100.00 |
Table 7.
Prevalence of IgM and IgG anti-T. gondii antibodies.
| Group 1 (2013–2016) | Group 2 (2019–2022) | |||||
|---|---|---|---|---|---|---|
| Anti-T. gondii IgG (−) | Anti-T. gondii IgG (+) | Total | Anti-T. gondii IgG (−) | Anti-T. gondii IgG (+) | Total | |
| ANTI-T. GONDII IGM (+) | 12 (5.48%) | 2 (0.53%) | 14 (2.36%) | 25 (2.25%) | 1 (0.06%) | 26 (0.90%) |
| ANTI-T. GONDII IGM (−) | 207 (94.52%) | 373 (99.47%) | 580 (97.64%) | 1086 (97.75%) | 1771 (99.94%) | 2857 (99.10%) |
| TOTAL | 219 (100%) | 375 (100%) | 594 (100%) | 1111 (100%) | 1772 (100%) | 2883 (100%) |
| ODDS | 0.058 | 0.005 | 0.024 | 0.023 | 0.001 | 0.009 |
| ODDS RATIO | 10.81 | 40.77 | ||||
| P VALUE | <0.001 * | <0.001 * | ||||
| 95% CI | 2.36–100.00 | 6.65–1674.49 | ||||
*: Statistical significant result.
Table 8.
IgG Anti-T. gondii antibodies seroprevalence in childbearing age women—spread in Dolj county, Romania, 2019–2022.
Table 8.
IgG Anti-T. gondii antibodies seroprevalence in childbearing age women—spread in Dolj county, Romania, 2019–2022.
| Town | Seroprevalence of Anti-T. gondii IgG Antibodies | Town | Seroprevalence of Anti-T. gondii IgG Antibodies |
|---|---|---|---|
| Podari | 58.97% | Coșoveni | 37.14% |
| Sadova | 57.58% | Bucovăț | 36.36% |
| Segarcea | 45.83% | Calafat | 34.29% |
| Teasc | 42.86% | Calopăr | 33.33% |
| Filiași | 41.94% | Malu Mare | 32.00% |
| Desa | 40.91% | Craiova | 31.63% |
| Mârșani | 40.91% | Dăbuleni | 31.58% |
| Băilești | 40.00% | Ciupercenii Noi | 18.18% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Radoi, C.L.; Zlatian, O.M.; Balasoiu, M.; Giubelan, L.; Stoian, A.C.; Dragonu, L.; Neacsu, A.; Iliescu, D.G. Toxoplasma gondii Seroprevalence and Trends in Women Presenting for Toxoplasma Screening in South-West Romania. Microorganisms 2023, 11, 2057. https://doi.org/10.3390/microorganisms11082057
AMA Style
Radoi CL, Zlatian OM, Balasoiu M, Giubelan L, Stoian AC, Dragonu L, Neacsu A, Iliescu DG. Toxoplasma gondii Seroprevalence and Trends in Women Presenting for Toxoplasma Screening in South-West Romania. Microorganisms. 2023; 11(8):2057. https://doi.org/10.3390/microorganisms11082057
Chicago/Turabian StyleRadoi, Cristiana Luiza, Ovidiu Mircea Zlatian, Maria Balasoiu, Lucian Giubelan, Andreea Cristina Stoian, Livia Dragonu, Alexandru Neacsu, and Dominic Gabriel Iliescu. 2023. "Toxoplasma gondii Seroprevalence and Trends in Women Presenting for Toxoplasma Screening in South-West Romania" Microorganisms 11, no. 8: 2057. https://doi.org/10.3390/microorganisms11082057
APA StyleRadoi, C. L., Zlatian, O. M., Balasoiu, M., Giubelan, L., Stoian, A. C., Dragonu, L., Neacsu, A., & Iliescu, D. G. (2023). Toxoplasma gondii Seroprevalence and Trends in Women Presenting for Toxoplasma Screening in South-West Romania. Microorganisms, 11(8), 2057. https://doi.org/10.3390/microorganisms11082057
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
